Bio Sequence

Gaining the Competitive Edge: Effective Strategies for Patent Retrieval and Analysis of ADC Drugs

26 September 2023
2 min read

Kadcyla, a HER2-targeted therapy, received approval and was launched in 2013. It is an antibody-drug conjugate (ADC) used as a single-agent treatment for HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxane-based chemotherapy, either as monotherapy or in combination. The drug combines trastuzumab, the active component of Herceptin, with DM1, a cytotoxic agent developed by ImmunoGen. DM1 is delivered to HER2-positive breast cancer cells through a stable linker called MCC.

Kadcyla exhibits dual anti-cancer properties: the HER2 inhibition of trastuzumab and the cytotoxicity of DM1. The following outlines the specific steps for patent retrieval of the ADC drug Kadcyla:

To begin with, register for a free account on the Patsnap Bio Sequence Database; on the database's homepage, enter "Kadcyla trastuzumab" in the drug/gene index search bar to quickly retrieve the sequence details of this antibody.

Next, click on the "View in Analytics" option in the upper right corner to access the patent database. You can then generate a search query for the ADC drug Kadcyla's monoclonal antibody Trastuzumab in the search box. Save this retrieval formula within the expert search library.

图形用户界面, 文本, 应用程序

描述已自动生成

Afterward, go to the Chemical database to search for the patent query for Kadcyla's linker MCC and its cytotoxic agent DM1, and save them separately in the expert search library.

图示

描述已自动生成

图形用户界面, 文本, 应用程序

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

By performing an AND operation within the expert search library and combining the three retrieval formulas, one can generate the patent retrieval results for the ADC drug Kadcyla.

图形用户界面, 文本, 应用程序

描述已自动生成

图形用户界面, 应用程序, Teams

描述已自动生成

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

Rani Therapeutics begins Phase 1 trial of RT-111
Latest Hotspot
3 min read
Rani Therapeutics begins Phase 1 trial of RT-111
26 September 2023
Rani Therapeutics Holdings proclaimed the launch of a Phase 1 clinical investigation assessing the safety and tolerability of RT-111.
Read →
Progress and Challenges in Targeted Cancer Metabolic Drugs - IDH2 inhibitors
Progress and Challenges in Targeted Cancer Metabolic Drugs - IDH2 inhibitors
26 September 2023
IDH2, or isocitrate dehydrogenase 2, is an enzyme that plays a crucial role in cellular metabolism.
Read →
Sulfathiazole Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
Drug Insights
4 min read
Sulfathiazole Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
28 September 2023
This article summarized the latest R&D progress of Sulfathiazole, the Mechanism of Action for Sulfathiazole, and the drug target R&D trends for Sulfathiazole.
Read →
Unleashing the Power of Streptozocin: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Streptozocin: A Comprehensive Review on R&D Breakthroughs
28 September 2023
This article summarized the latest R&D progress of Streptozocin, the Mechanism of Action for Streptozocin, and the drug target R&D trends for Streptozocin.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.